You are here

Academic, AstraZeneca Scientists Join to Study Key Risk Factor for Alzheimer’s Disease

Under the terms of the new collaboration, called the A5 Alliance, AstraZeneca will fund the academic research, and members of the company’s Neuroscience Innovative Medicines unit will manage the program and contribute scientific expertise. The academic members of the alliance will contribute their disease-area knowledge and expertise, as well as lead specific aspects of the research program in their laboratories.

Dr. Steven Paul, principal academic collaborator, said: “We are convinced that ApoE represents a major piece of the Alzheimer's disease puzzle and that each member of the A5 Alliance brings a critical piece of that puzzle to the table."

The ApoE genotype is considered second only to age as a risk factor for the development of Alzheimer's disease. Drug discovery efforts involving the genotype have been hindered, however, by the challenging biology and by a lack of in vivo models.

Source: Weill-Cornell news release

Recent Headlines

First New Medication for Seizure Clusters in More Than Two Decades
Novel, Low-cost Device Highly Accurate at Screening Newborn Jaundice
Mode Delivers Antivirals Safely, Cheaply to Remote Regions
First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status